London open: Stocks surge after latest poll results
20th Jun 2016 08:48
(ShareCast News) - Stocks in London surged at the start of trading, alongside the largest gain the pound in three months, with investors taking their cue from strong gains in Asia as Brexit polls showed the Remain campaign was in the lead. As of 08:43 BST the FTSE 100 was 145.82 points or 2.42% high
Read moreGSK breathes easier after successful triple-COPD trial
20th Jun 2016 07:16
(ShareCast News) - Late-stage drug trials by GlaxoSmithKline on its treatment for chronic obstructive pulmonary disease (COPD) have proved successful. European and US regulatory submission are likely to be completed the end of 2016 based on the data from this Phase III clinical test by GSK and its r
Read moreGSK's Head of Vaccines to step down
14th Jun 2016 11:59
(ShareCast News) - GlaxoSmithKline's head of vaccines announced his decision to retire after nearly three decades of service to the firm, including a decade as a member of the board. Dr Moncef Slaoui, Chairman, Vaccines agreed with the Board that he would step down from his post on 30 June 2017. Ph
Read moreDirectors dealings: NAIT boosts stake in EKF Diagnostics to 14.1%
10th Jun 2016 14:11
(ShareCast News) - Harwood Capital, acting as investment manager on behalf of North Atlantic Smaller Companies Investment Trust PLC, picked up another large batch of shares in EKF Diagnostics. Christoper Mills, who was named to the post of non-executive chairman at the global point-of-care medical d
Read moreGlaxoSmithKline brings forward COPD application in US by over a year
2nd Jun 2016 07:11
(ShareCast News) - GlaxoSmithKline has, after discussions with the US regulator, accelerated the new drug application for its daily closed triple therapy for chronic obstructive pulmonary disease (COPD). GSK and its partner in the drug, Innoviva, now expect to make the US regulatory submission befor
Read moreGlaxoSmithKline announces positive results from Relvar Ellipta study
24th May 2016 11:48
(ShareCast News) - GlaxoSmithKline and Innovia announced positive headline results from their Salford lung study of Relvar Ellipta in the treatment of chronic obstructive pulmonary disease (COPD). The study showed Relvar Ellipta achieved a superior reduction in exacerbations versus usual care in pat
Read moreSunday newspaper round-up: RBS, Shell, Cobham, BT, banks
15th May 2016 17:01
(ShareCast News) - Royal Bank of Scotland is examining a range of radical options to help speed the long-delayed separation and flotation of its Williams & Glyn subsidiary, including a potential divestment of its NatWest brand. Banking sources have indicated to the Sunday Telegraph that RBS and its
Read moreGlaxoSmithKline first-quarter sales up 11% but profit falls
27th Apr 2016 12:02
(ShareCast News) - GlaxoSmithKline posted a rise in first-quarter sales and core earnings per share amid healthy demand for the company's new drugs. First-quarter sales were up 11% in sterling terms to £6.2bn, with core earnings per share 14% higher at 19.8p, beating analysts' forecasts of 17.9p. N
Read moreFTSE 100 movers: Standard Chartered lifted while AstraZeneca sinks
26th Apr 2016 14:25
(ShareCast News) - The FTSE 100 was treading water on Tuesday afternoon, managing to keep itself in the black in contrast to its sibling index. Emerging markets-exposed bank Standard Chartered was among the top performers, as investors showed their approval of the bank's ongoing turnaround. It poste
Read moreDirector dealings: Hikma gets shot in the arm as chief tops up
20th Apr 2016 16:38
(ShareCast News) - Hikma Pharmaceuticals's chief Said Darwazah boosted his stake in the generic drugs firm on Wednesday to 5.49% through the acquisition of 30,000 shares at an individual price of 2,271p. The transaction was carried out by Vidacos Nominees on behalf of Darhold Limited, in which Darwa
Read moreThursday broker round-up
14th Apr 2016 14:09
(ShareCast News) - Metro Bank: Goldman Sachs reiterates neutral with a target price of 2080p. Burberry: Credit Suisse stays at underperform with a target price of 1050p. JD Sports: Investec keeps at buy with a target price of 1420p and Cantor Fitzgerald reiterates buy with a target of 1400p. Tesco
Read moreThursday broker round-up
7th Apr 2016 15:32
(ShareCast News) - Zoopla: UBS downgrades to neutral with a target price of 260p. Caledonia Mining: Panmure Gordon downgrades to hold, 61p target. Burberry: RBC downgrades underperform with a target price of 1300p, JP Morgan reiterates neutral with a target of 1400p and UBS keeps at buy with a targ
Read moreLondon close: Stocks jump on gains in big pharma and rally in oil prices
6th Apr 2016 16:46
(ShareCast News) - London stocks advanced on Wednesday as oil prices regained strength and investors awaited the Federal Reserve's meeting minutes, which were due out later in the day. Oil prices rose, lifted by a 'bullish' report on the state of weekly US stockpiles of commercial crude. Hopes t
Read moreLondon-listed pharmas rally as Pfizer-Allergan deal collapses
6th Apr 2016 10:20
(ShareCast News) - Shares in pharmaceuticals companies Shire, AstraZeneca and GlaxoSmithKline rallied on Wednesday as investors bet that the termination of Pfizer's agreement to buy Allergan might make the London-listed companies bid targets. US drug maker Pfizer said on Wednesday that its $160bn ag
Read moreTuesday broker round-up
5th Apr 2016 15:09
(ShareCast News) - Royal Mail: Investec reiterates buy with a target price of 580p. Gooch Housego: Investec reiterates buy, 1020p target and Finncap keeps at hold. Glencore: Exane BNP Paribas maintains outperform with a target price of 165p. Babcock: JP Morgan reiterates overweight with a targe
Read more